Compare EHang Holdings Ltd - ADR (EH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Recursion Pharmaceuticals Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.09 (market cap $314.00M), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 7.4× EHang Holdings Ltd - ADR's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EH | RXRX | |
|---|---|---|
Market Cap | $314.00M | $2.31B |
Volume | 856,650 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $18.94 | $6.79 |
52-Week Low | $4.03 | $2.84 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | $265.69M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical outlook and mixed financials. Revenue declined to $418M in 2025 with a net loss of $276M, though gross margins remain strong at 61.5%. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a cautious sentiment.
The outlook is challenged by persistent losses and regulatory scrutiny, but the company's cash position of $1.12B provides some buffer. Investment opportunities lie in the nascent eVTOL market, while risks include execution missteps and intense competition. Analyst consensus is divided, reflecting high uncertainty.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
